Multi-cancer screening market is gaining significant traction across the world. Multi-cancer screening has the potential to find more than one type of cancer from a single sample of blood. Several types of multicancer screening tests that are currently accessible in the world include blood tests, imaging tests, genetic tests, liquid biopsy, stool tests, and others. Among various types of tests, the liquid biopsy test is the most prominent since it can be carried out rapidly, provides genomic, proteomic, and metabolomic information, and is less invasive than tissue biopsies. Breast cancer, lung cancer, colorectal cancer, pancreatic cancer, liver cancer, ovarian cancer, stomach cancer, esophageal cancer, and prostate cancer are some of the cancer types that can be easily detected through multi-cancer screening tests. The increasing prevalence of cancer in various countries of the world especially Australia, New Zealand, Ireland, Hungary, and the United States of America is increasing the demand for multicancer screening tests during the forecast period. Growth in the support provided by the government to improve the quality of medical services provided in every country is also propelling the global multicancer screening market in the forecast period. Moreover, the government is actively participating in taking preventive measures, for controlling the prevalence of cancer in every country by the implementation of new health policies and introduction of healthcare insurance every year. Furthermore, the growth in the geriatric population of the country and the increase in the prevalence of certain types of cancers, which are associated with people, especially during their elder age is also expected to boost the global multicancer screening market in upcoming years.
According to the report published by the World Health Organization (WHO) in 2022, around 2.26 million cases of breast cancer were worldwide in 2020, followed by 2.21 million cases of lung cancer, 1.93 million cases of colon and rectum cancer, 1.41 million cases of prostate cancer, 1.20 million cases of skin cancer (non-melanoma) and 1.09 million cases of stomach cancer.
Download Free Sample ReportGrowth in Government Support
Moreover, governing bodies of every country also launch public awareness campaigns to promote cancer screening and early detection. These campaigns focus on educating people about the importance of regular screening for cancer and encourage them to get screened.
Furthermore, governments can collaborate with private companies and organizations to advance cancer screening technologies. In the case of cancer screening programs,
. According to the report published by Union for International Cancer Control (UICC) in 2023, it has been observed that around 7.2 million of those above 70 years of age were diagnosed with cancer and approximately 4.4 million of them resulted in death due to cancer.
Recent Developments
- In March 2021, AgilentTechnologies, Inc. made an agreement to acquire Resolution Bioscience Inc. toexpand the company’s NGS-based cancer diagnostics and its fast-growingprecision medicine segment. This agreement was made for US$ 550 million in cashat closing and an additional US$ 145 million when the company achieves futureperformance milestones.
- In December 2022, IntegratedDNA Technologies, Inc. acquired Invitae Corporation.’s next-generationsequencing (NGS) research assays with the Archer trademark for US$ 48 million.
- In January 2023, LaboratoryCorporation of America Holdings. acquired Personal Genome Diagnostics for US$ 450million and another US$ 125 million as contingent milestone payments. PersonalGenome Diagnostics was a next-generation sequencing test maker, and with thisacquisition, Laboratory Corporation of America Holdings. has increased its NGStesting portfolio.
- In January 2023, FOUNDATIONMEDICINE, INC. (F. Hoffmann-La Roche Ltd) got FDA approval for itsFoundationOne Liquid CDx as a companion diagnostic for Rozlytrek. This test isrelevant for ROS1+NSCLC patients and NTRK fusion-positive solid tumorspatients.
- In January 2023, Burning RockDX got an FDA Breakthrough Device Designation for its Multi-Cancer DetectionBlood Test called OverC. This test is intended for the detection of lung,liver, ovarian, esophageal, and pancreatic cancer for adults aged between 50and 75 years.
Market Segmentation
Market Players
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, Volume in tons, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, Volume forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | Test Type Technology Sample Method Cancer Type Application End User |
| Regional Scope | North America; Asia Pacific; Europe; South America; Middle East & Africa |
| Country Scope | United States, Canada, Mexico, China, India, Japan, Australia, South Korea, Germany, France, United Kingdom, Spain, Italy, Brazil, Argentina, Colombia, South Africa, UAE, and Saudi Arabia |
| Key Companies Profiled | Agilent Technologies, Inc., Atara Biotherapeutics, Inc., Burning Rock Biotech Limited, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Genecast Biotechnology Co., Ltd., Guardant Health, Inc., Illumina, Inc. (GRAIL, LLC.), Konica Minolta, Inc. and (Ambry Genetics) |
| Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
